The clinical development of FLT3 inhibitors in acute myeloid leukemia

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.10, 2011-10, pp. : 1377-1395

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By Alvarado Yesid Kantarjian Hagop M. Luthra Rajyalakshmi Ravandi Farhad Borthakur Gautam Garcia-Manero Guillermo Konopleva Marina Estrov Zeev Andreeff Michael Cortes Jorge E.

Cancer, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

Blackwell Publishing

Access to resources Recommend Favorite

FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications

Current Pharmaceutical Design, Vol. 11, Iss. 26, 2005-10 ,pp. : 3449-3457

Bentham Science Publishers

Access to resources Recommend Favorite

Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD–negative acute myeloid leukemia

By Qu Shuang Liu Bin Guo Xiaoling Shi Hongshun Zhou Meifeng Li Li Yang Shulan Tong Xiuzhen Wang Haihe

Cancer, Vol. 120, Iss. 14, 2014-07 ,pp. : 2130-2141

Blackwell Publishing

Access to resources Recommend Favorite

Pgp and FLT3: Identification and Modulation of Two Proteins that Lead to Chemotherapy Resistance in Acute Myeloid Leukemia

Current Medicinal Chemistry, Vol. 14, Iss. 5, 2007-02 ,pp. : 519-530

Bentham Science Publishers

Access to resources Recommend Favorite

FLT3 as a Therapeutic Target in Childhood Acute Leukemia

Current Drug Targets, Vol. 8, Iss. 6, 2007-06 ,pp. : 703-714

Bentham Science Publishers

Access to resources Recommend Favorite